Cover Image
市場調查報告書

腎盂腎炎:開發平台分析

Pyelonephritis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251523
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
腎盂腎炎:開發平台分析 Pyelonephritis - Pipeline Review, H2 2015
出版日期: 2015年07月22日 內容資訊: 英文 48 Pages
簡介

所謂腎盂腎炎是特殊的一種泌尿道感染(UTI),通常從尿道和膀胱發病再轉到腎臟。主要的症狀·前兆有發熱和腹痛,頻繁的排尿,噁心嘔吐,意識混濁,背部痛·側腹部痛等。主要的致病因子包含了免疫系的弱化,及膀胱週邊神經的損傷等。主要的治療方法有抗生素等。

本報告提供全球各國治療腎盂腎炎所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

腎盂腎炎概要

治療藥的開發

  • 腎盂腎炎開發中產品:概要
  • 腎盂腎炎開發中產品:比較分析

企業正在開發的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

企業開發中的產品

治療藥的開發企業

  • Achaogen Inc.
  • AstraZeneca Plc
  • Merck & Co., Inc.
  • MerLion Pharmaceuticals Pte Ltd
  • The Medicines Company

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (ceftazidime + avibactam sodium)
  • (meropenem+ RPX-7009)
  • finafloxacin
  • plazomicin sulfate
  • relebactam

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6914IDB

Summary

Global Markets Direct's, 'Pyelonephritis - Pipeline Review, H2 2015', provides an overview of the Pyelonephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pyelonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pyelonephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pyelonephritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pyelonephritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pyelonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pyelonephritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pyelonephritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pyelonephritis Overview
  • Therapeutics Development
    • Pipeline Products for Pyelonephritis - Overview
    • Pipeline Products for Pyelonephritis - Comparative Analysis
  • Pyelonephritis - Therapeutics under Development by Companies
  • Pyelonephritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Pyelonephritis - Products under Development by Companies
  • Pyelonephritis - Companies Involved in Therapeutics Development
    • Achaogen Inc.
    • AstraZeneca Plc
    • Merck & Co., Inc.
    • MerLion Pharmaceuticals Pte Ltd
    • The Medicines Company
  • Pyelonephritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ceftazidime + avibactam sodium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (meropenem+ RPX-7009) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • relebactam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pyelonephritis - Recent Pipeline Updates
  • Pyelonephritis - Dormant Projects
  • Pyelonephritis - Discontinued Products
  • Pyelonephritis - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)
      • May 15, 2012: Achaogen Provides Update On Phase II Study Of Plazomicin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pyelonephritis, H2 2015
  • Number of Products under Development for Pyelonephritis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Pyelonephritis - Pipeline by Achaogen Inc., H2 2015
  • Pyelonephritis - Pipeline by AstraZeneca Plc, H2 2015
  • Pyelonephritis - Pipeline by Merck & Co., Inc., H2 2015
  • Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2015
  • Pyelonephritis - Pipeline by The Medicines Company, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Pyelonephritis Therapeutics - Recent Pipeline Updates, H2 2015
  • Pyelonephritis - Dormant Projects, H2 2015
  • Pyelonephritis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Pyelonephritis, H2 2015
  • Number of Products under Development for Pyelonephritis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top